Raven observers show emotional contagion with raven demonstrators experiencing an unpleasant affect
MedUni Vienna: Ebola: global network including MedUni Vienna draws up Public Health models for better understanding of epidemics
The tenth Ebola outbreak since the emergence of this virus is now shaking the Congo. The Health Ministry of this central...
Twitter @lifesciencevieTweets @lifesciencevie
13th Annual Conference on Health Informatics meets Digital Health "From eHealth to dHealth"
In collaboration with LISAvienna, Boehringer Ingelheim invites the regional biomedical community to join personalized...
It starts with one... Advances in biotech begin with one meeting, one theory, one trial, one breakthrough. You make it...
Innovative rekonstruktive Ansätze zu Wiederherstellungsmöglichkeiten an der Grenze zwischen Mensch und Maschine
Political stability is a major factor when considering major investments in a country. Austria scores very highly in that regard, as it does in terms of infrastructure and standard of living. Without a doubt, however, one of the most important considerations for a research-driven company is research subsidies. This also played a decisive role in the decision to invest 700 million euros in the construction of our new biopharmaceutical production facility in Vienna. We are looking for highly qualified candidates to fill the 500 new positions, created for this project, and attach great importance for that reason to the training and qualifications of potential employees.
Philipp von Lattorff
Managing Director at Boehringer Ingelheim RCV GmbH & Co KG